Jung Eun Park, Mikang Lee, Seong‐Chul Kim, Yanqiao Zhang, James P. Hardwick, Yoon Kwang Lee – 8 November 2017 – Peroxisome proliferator‐activated receptor gamma (PPARγ) is a master regulator for white adipocyte differentiation and lipid storage. The increased level of hepatic PPARγ2 isoform reprograms liver for lipid storage and causes abnormal fat accumulation in certain pathophysiologic conditions. The current study aimed to investigate a role of transcriptional repressor hairy and enhancer of split 6 (HES6) in the regulation of Pparg2 expression and hepatic steatosis induced by diet.

Teresa García‐Lezana, Imma Raurell, Miren Bravo, Manuel Torres‐Arauz, María Teresa Salcedo, Alba Santiago, Andreu Schoenenberger, Chaysavanh Manichanh, Joan Genescà, María Martell, Salvador Augustin – 7 November 2017 – Portal hypertension (PH) drives most of the clinical complications in chronic liver diseases. However, its progression in nonalcoholic steatohepatitis (NASH) and its association with the intestinal microbiota (IM) have been scarcely studied. Our aim was to investigate the role of the IM in the mechanisms leading to PH in early NASH.

Wen‐Juei Jeng, Yi‐Cheng Chen, Rong‐Nan Chien, I‐Shyan Sheen, Yun‐Fan Liaw – 6 November 2017 – Hepatitis B surface antigen (HBsAg) loss is a rare event during nucleos(t)ide analogue (Nuc) therapy. Limited data suggest that stopping Nuc therapy may increase HBsAg loss rate in hepatitis B e antigen–negative patients. A large study was conducted to investigate this issue in more detail. Of the 1,075 hepatitis B e antigen–negative patients treated with Nuc for a median of 156 (61‐430) weeks, 5 showed HBsAg seroclearance during treatment at an estimated annual incidence of 0.15%.

Olympia E. Anastasiou, Foteini Almpani, Anke Herrmann, Guido Gerken, Markus Ditschkowski, Sandra Ciesek – 6 November 2017 – Hepatitis B virus (HBV) reactivation (HBVr) in recipients of allogeneic hematopoetic stem cells (aHSCs) appears heterogeneously with respect to its frequency, manifestation, and outcome. The aim of this study was to present data from a large German cohort of recipients of aHSC transplantation (aHSCT), focusing on the incidence of HBVr in antibody to hepatitis B core antigen (anti‐HBc)‐positive aHSCT recipients, its clinical outcome, and the role of mutations in HBV.

Dar‐In Tai, Wen‐Juei Jeng, Chun‐Yen Lin – 6 November 2017 – Genome‐wide association studies have indicated that human leukocyte antigen (HLA)‐DP and HLA‐DQ play roles in persistent hepatitis B virus (HBV) infection in Asia. To understand the evolution of HBV‐related single nucleotide polymorphisms (SNPs) and to correlate these SNPs with chronic HBV infection among different populations, we conducted a global perspective study on hepatitis‐related SNPs. We selected 12 HBV‐related SNPs on the HLA locus and two HBV and three hepatitis C virus immune‐related SNPs for analysis.

Cyrielle Caussy, Mosab H. Alquiraish, Phirum Nguyen, Carolyn Hernandez, Sandra Cepin, Lynda E. Fortney, Veeral Ajmera, Ricki Bettencourt, Summer Collier, Jonathan Hooker, Ethan Sy, Emily Rizo, Lisa Richards, Claude B. Sirlin, Rohit Loomba – 6 November 2017 – The optimal threshold of controlled attenuation parameter (CAP) for the detection of hepatic steatosis using both M and XL probe is unknown in nonalcoholic fatty liver disease (NAFLD).

Cameron Sikavi, Phillip H. Chen, Alex D. Lee, Elena G. Saab, Gina Choi, Sammy Saab – 6 November 2017 – The treatment of chronic hepatitis C (HCV) in human immunodeficiency virus 1 (HIV)–infected individuals has been historically marked by low sustained virologic response (SVR) rates in comparison to those without HIV infection, resulting in the Food and Drug Administration labeling those coinfected as a “special population with an unmet medical need.” We systematically reviewed the treatment of chronic HCV infection in those infected with HIV.

Kenneth E. Sherman, Marion G. Peters, David Thomas – 6 November 2017 – Among persons living with human immunodeficiency virus (HIV) infection, liver disease remains a major cause of morbidity and mortality. While the etiologies are varied and often overlapping in the individual patient, the underlying mechanisms, including oxidative stress, direct activation of stellate cells, HIV interaction with hepatocytes, and bacterial translocation with systemic immune activation, seem to be unifying characteristics.

Chetan Kalal, Akash Shukla, Ravi Mohanka, Samir Shah – 6 November 2017

Aditi Varshney, Jiban J. Panda, Avishek K. Singh, Nitin Yadav, Chhagan Bihari, Subhrajit Biswas, Shiv K. Sarin, Virander S. Chauhan – 6 November 2017 – Hepatocellular carcinoma (HCC) is an aggressive tumor with limited systemic and locoregional modalities of treatment. Although microRNA (miRNA) based therapies have significant potential, their targeted delivery remains a major challenge. miR‐199a‐3p functions as an important tumor suppressor in HCC, which regulates various cellular processes.